Immutep Ltd (AU:IMM)
ASX:IMM
Want to see AU:IMM full AI Analyst Report?
IMM Stock Chart & Stats
AU$0.07
-AU$0.01(-2.94%)
At close: 4:00 PM EST
AU$0.07
-AU$0.01(-2.94%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.47
Previous CloseN/A
Volume844.76K
Average Volume (3M)4.11M
Market Cap
AU$78.11M
Enterprise ValueAU$7.52M
Total Cash (Recent Filing)AU$99.13M
Total Debt (Recent Filing)AU$2.16M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Sep 02, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.17Price Target Upside142.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$26.73M
Bulls Say, Bears Say
Bulls Say
Platform & PipelineA proprietary LAG-3 platform with multiple clinical-stage candidates (efti, leramilimab and others) is a durable competitive asset in immuno-oncology. A diversified pipeline reduces single-asset binary risk, enables multiple value-inflection points and supports partner interest over years.
Conservative Balance SheetLow leverage and a healthy equity base provide structural financial flexibility for a clinical-stage biotech. Conserved debt levels lower fixed obligations, increasing runway options and reducing solvency risk while management pursues clinical milestones and partnerships.
Partnering & Financing ModelA business model built on collaborations, milestone payments and equity financing aligns with industry norms for pre-commercial biotechs. Durable partner funding and licensing can de-risk programs, transfer development costs and provide staged capital tied to clinical progress.
Bears Say
Persistent LossesSustained negative margins across gross, operating and net lines indicate the company cannot yet generate product economics. This structural unprofitability limits the ability to self-fund development, raises dependence on external capital and increases dilution risk over multiple funding rounds.
Weak Cash GenerationMaterial negative operating and free cash flows are a durable constraint on strategy: they necessitate recurrent fundraising, can delay programs if financing conditions tighten, and force trade-offs between assets. Persistent cash burn elevates execution and dilution risk.
Pre-commercial Execution RiskBeing pre-commercial with limited employees and no product revenues concentrates execution risk: clinical, regulatory and manufacturing challenges require sustained technical capability and external capital. Small headcount and project scale heighten dependence on partners and timely financing.
Immutep Ltd News
IMM FAQ
What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest share price was AU$0.03 and its highest was AU$0.47 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is AU$78.11M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s upcoming earnings report date is Sep 02, 2026 which is in 94 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Feb 24, 2026. The company reported -AU$0.03 earnings per share for the quarter, missing the consensus estimate of -AU$0.028 by -AU$0.002.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,473,721,300 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -AU$0.03 in its last earnings report, missing expectations of -AU$0.028. Following the earnings report the stock price went up 1.299%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in AU:IMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.17 (142.86% Upside)
AU$0.17 (142.86% Upside)
Blogger Sentiment
Bullish
AU:IMM Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.33%
12-Months-Change
Fundamentals
Return on Equity
-69.20%
Trailing 12-Months
Asset Growth
-13.05%
Trailing 12-Months
Company Description
Immutep Ltd
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
IMM Stock 12 Month Forecast
Average Price Target
AU$0.17
▲(142.86% Upside)
Technical Analysis
Imugene
―
Mesoblast Limited
―
Starpharma Holdings Limited
―
Telix Pharmaceuticals
―
Radiopharm Theranostics Limited
―
Options Prices
Currently, No data available
---